研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

移植中的 HHV-8 相关疾病:病例报告和叙述性回顾侧重于诊断和预防。

HHV-8-associated diseases in transplantation: A case report and narrative review focused on diagnosis and prevention.

发表日期:2024 Jul 07
作者: Olivia S Kates, Heather McDade, Francis J Tinney, Sharon R Weeks-Groh, Kathryn Lurain
来源: CYTOKINE & GROWTH FACTOR REVIEWS

摘要:

人类疱疹病毒 8 (HHV-8) 或卡波西肉瘤疱疹病毒 (KSHV) 是一种机会性肿瘤病毒,可引起多种病理实体。我们报告了一例致命的 HHV-8 相关多系统疾病,包括播散性卡波西肉瘤和 HHV8 相关淋巴组织增生性疾病,全身炎症。我们对移植中 HHV-8 的文献进行了叙述性回顾,目的是阐明这一弱势群体中 HHV-8 相关疾病的范围、疾病传播模式以及供体和受体筛查的潜在作用。 8 相关 KS、原发性渗出性淋巴瘤 (PEL)、多中心 Castleman 病 (MCD) 和 KSHV 炎性细胞因子紊乱 (KICS) 可能会影响移植受者;除 KS 外,这些病症很少见,但发病率和死亡率很高。HHV-8 相关疾病在移植受者中具有多样且多变的表现,可能具有致命的结果。器官捐献者中的 HHV-8 血清流行率以及捐献者源性 HHV-8 感染或临床重大疾病的风险程度仍然未知,需要进一步研究。© 2024 Wiley periodicals LLC。
Human herpes virus 8 (HHV-8) or Kaposi sarcoma herpesvirus (KSHV) is an opportunistic oncovirus that causes multiple pathologic entities.We present a case of fatal HHV-8-associated multisystem illness with disseminated Kaposi sarcoma and HHV8-associated lymphoproliferative disorder with systemic inflammation. We conducted a narrative review of the literature on HHV-8 in transplantation with a goal of illuminating the spectrum of HHV-8-associated diseases in this vulnerable population, modes of disease transmission, and the potential role for donor and recipient screening.HHV-8-associated KS, primary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and KSHV inflammatory cytokine disorder (KICS) may affect transplant recipients; with the exception of KS, these conditions are rare but carry high morbidity and mortality.HHV-8-associated diseases have diverse and protean manifestations in transplant recipients, with potentially fatal outcomes. HHV-8 seroprevalence among organ donors and the magnitude of risk for donor-derived HHV-8 infection or clinically significant disease remain unknown and require further study.© 2024 Wiley Periodicals LLC.